Neogene Therapeutics is a pre-clinical stage biotechnology company pioneering the development of next-generation, fully personalized engineered T cell therapies for a broad spectrum of cancers. The Company’s engineered T cells target tumor-specific mutation-derived neo-antigens, that render tumor cells vulnerable to detection and destruction by T cells. Neogene’s proprietary technology platform aims to identify T cell receptor genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of T cell receptor genes for each individual patient, which will be engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.